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Summary 
Background  Neurofibromatosis type 1 is a common genetic disorder characterised by neurocutaneous manifestations and cognitive and behavioural problems. Statins were shown to reduce analogous learning deficits in a mouse model of the disease, but a short-term trial in humans was inconclusive. We aimed to assess the use of simvastatin for the improvement of cognitive and behavioural deficits in children with neurofibromatosis type 1 for 12 months. 
 
Methods  In this randomised, double-masked, placebo-controlled trial, we recruited children with genetically confirmed neurofibromatosis type 1 aged 8–16 years from two national referral centres in the Netherlands and Belgium. Those with symptomatic CNS abnormalities or on neurotropic medication, including stimulants, were excluded. Eligible patients were randomly assigned (1:1) via a computer-generated, permuted-block list to simvastatin (10 mg per day in month 1, 20 mg per day in month 2, and 20–40 mg per day in months 3–12) or placebo for 12 months. Investigators, participants, and parents were masked to treatment assignment. Primary outcome measures were full-scale intelligence (Wechsler intelligence scale for children), attention problems (child behaviour checklist, parent-rated [CBCL]), and internalising behavioural problems (CBCL). We did intention-to-treat analyses (of all patients who had outcome data) using linear regression of the 12 month outcome scores, adjusted for baseline performance. This trial is registered with the Netherlands Trial Register, number NTR2150. 
 
Findings  We randomly assigned 84 children to a treatment group (43 to simvastatin, 41 to placebo) between March 9, 2010, and March 6, 2012. We did not assess outcomes in two patients in the placebo group because they needed additional drug therapy. Simvastatin for 12 months had no effect on full-scale intelligence (treatment effect compared with placebo –1•3 IQ points [95% CI –3•8 to 1•3]; p=0•33), attention problems (–1•6 T-score points [–4•3 to 
1•0]; p=0•23), and internalising behavioural problems (–0•1 T-score points [–3•3 to 3•1]; 
p=0•96). 38 (88%) of 43 patients on simvastatin and 39 (95%) of 41 patients on placebo reported adverse events, which were serious in two and four patients, respectively. 
 
Interpretation  12 month simvastatin treatment did not ameliorate cognitive deficits or behavioural problems in children with neurofibromatosis type 1. The use of 20–40 mg simvastatin per day for cognitive enhancement in children with neurofibromatosis type 1 is not recommended.  
Funding  The Netherlands Organization for Health Research and Development (ZonMw), Research Foundation Flanders (FWO-Vlaanderen), Marguerite-Marie Delacroix Foundation, and the 
Dutch Neurofibromatosis Association (NFVN). 
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Introduction 
Neurofibromatosis type 1 is a common autosomal-dominant disorder, with a prevalence of 1 in every 2500–3000 births.1 It is caused by loss-of-function mutations in the NF1 gene, 
which encodes neurofibromin, a negative regulator of rat-sarcoma viral oncogene 
homologue (Ras). Neurofibromatosis type 1 is characterised by cutaneous café-au-lait 
spots, neurofibromas, and cognitive and behavioural problems.2 Up to 80% of children aged 6–18 years with neurofibromatosis type 1 present with moderate to severe impairment in one or more areas of cognitive functioning, and 40% attend special education.3,4 Moreover, 30–40% of children with neurofibromatosis type 1 fulfil criteria for 
attention deficit hyperactivity disorder and up to 60% have problems with executive functioning.3,5 The average intelligence quotient (IQ) is 10–15 points lower in these children than in population or sibling control groups.3,6 Parents of children with 
neurofibromatosis type 1 frequently report difficulties in their child’s social daily life activities and a high rate of internalising behavioural problems, such as anxiety or mood disorders.7 Taken together, cognitive and behavioural deficits lead to lower academic achievement and loss of quality of life,4,8,9 persisting into adulthood.10 The learning and 
attention deficits noted in patients with neurofibromatosis type 1 are reported in the Nf1+/– mouse model,11–13 accompanied by a decrease in synaptic plasticity.11–13 These animal 
studies have shown that the plasticity and behavioural deficits are reversed by reducing Ras activity.11,14 Ras activity requires farnesylation, which allows Ras to anchor to the plasma membrane where it can be activated by growth-factor receptors and their adaptor proteins. Since cholesterol is an obligate precursor of farnesyl, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase have been suggested as a potential therapy for neurofibromatosis type 1. Indeed, lovastatin normalised Ras activity, rescued 
synaptic plasticity deficits, and restored learning and attention deficits in the Nf1+/– mouse model.14 Results of a small, open-label, single-arm study of lovastatin in children with 
neurofibromatosis type 1 suggested that lovastatin improved memory and attention, and normalised default network functional connectivity measured with resting state functional MRI.15,16 However, lovastatin is not approved or marketed in many parts of the world, including the European Union. The closest approved alternative, simvastatin, is similar in structure, pharmacokinetics, and blood–brain barrier permeability. Moreover, simvastatin is a slightly more potent inhibitor of HMG-CoA reductase and is better at reducing HMG-CoA reductase activity in neurons than is lovastatin.17,18 Although findings of a randomised controlled trial reporting the short-term effect of simvastatin in children with 
neurofibromatosis type 1 showed no effect after 12 weeks on a set of primary outcome measures,6 a significant improvement was reported for a secondary outcome measure, the object assembly subtask of the Dutch translation of the third edition of the Wechsler 
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intelligence scale for children (WISC-III-NL).6 Although this trial had an overall negative 
outcome, it had some limitations that might have affected its results: children on stimulant- medication were not excluded, and 12 week treatment was short, with only 4 weeks at the highest target dose. A longer treatment duration would have allowed the assessment of the 
effects on global cognitive functioning, daily life functioning, and behaviour, and might have 
been necessary to show clinical benefits. Given the large amount of safety data in children6,19 and worldwide marketing authorisation of simvastatin, we aimed to improve upon the limitations of this previous trial by assessing the use of simvastatin for the treatment of cognitive and behavioural 
deficits in children with neurofibromatosis type 1 for 12 months. 
Methods 
Study design and participants  We undertook this randomised, parallel-group, placebo-controlled trial in two national referral centres: Erasmus MC (Rotterdam, Netherlands) and UZ Leuven (Leuven, Belgium). We screened patients aged 8–16 years with genetically confirmed neurofibromatosis type 
1 for eligibility. Genetic counselling and testing for neurofibromatosis type 1 is part of routine care and was done independently of this trial. The rationale for genetic 
confirmation was the substantial overlap in phenotypes between neurofibromatosis type 1 and related disorders (eg, Legius syndrome).20 Exclusion criteria were: use of neurotropic medication, including stimulant, anti- psychotic, antiepileptic, antianxiety, and 
antidepressant drugs, or current simvastatin use; symptomatic CNS abnormalities; 
insufficient comprehension of the Dutch language; severely impaired vision or deafness; 
segmental neurofibromatosis type 1; or an IQ below 48. We obtained informed oral and written consent from parents and assent from children of 12 years and older. Local and national institutional review boards approved the protocol. The trial was done in agreement with the Declaration of Helsinki (version 2008) and Good Clinical Practice guidelines. 
Randomisation and masking Eligible patients were randomly assigned (1:1) by the local hospital pharmacist to simvastatin or matched placebo according to computer-generated, permuted block 
randomisation lists (ten participants per block, stratified by centre) that were provided by the Department of Biostatistics, Erasmus MC, with medication numbers in the order of enrolment. All investigators, participants, and their parents were masked to treatment allocation. We achieved blinding by using capsules of identical colour, shape, size, weight, smell, and taste. 
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Procedures Participants took 10 mg per day of simvastatin or matched placebo once daily in the 
morning during the first month and 20 mg per day once daily in the morning during the second month. During months 3–12, dosing was fixed at 20 mg per day for children aged 12 years and younger and 40 mg per day for adolescents older than 12 years. We assessed 
efficacy outcome measures at baseline and at the end of month 12 of treatment. Since no standard measure exists to assess improvement of cognition in patients with 
neurofibromatosis type 1, we included a broad range of validated tests and questionnaires 
that are sensitive to the cognitive and behavioural deficits in this group of patients. Outcome measures included constructs that were similar to those that improved in mouse models receiving statins:14 visual-spatial memory and attention; improvements in daily life 
behavioural problems rated by parents; and global cognitive functioning. We used three primary outcome measures that are relevant to daily life functioning and academic achievement: full-scale intelligence (WISC-III-NL),4,6 parent-reported attention problems (child behaviour checklist [CBCL]21), and parent-reported internalising behavioural problems (CBCL). The attention problems scale of the CBCL consists of items screening for problems in directing and sustaining attention, controlling impulsivity, and hyperactivity. Secondary outcomes were visual-spatial memory (Rey complex figure test–delayed recall),6 attention (Stroop colour–word interference test),6 teacher-reported school performance (teacher report form),21 parent-reported psychosocial quality of life (child health questionnaire–parent form 50 [CHQ-PF50]),9 patient-reported internalising behavioural problems (youth self-report [YSR] form, completed by patients aged ≥11 years),21 and fine motor coordination (grooved pegboard test).8 All neuropsychological tests were developed for children and were written or presented in Dutch. For most outcome measures, we used age-standardised scores. The mean average IQ for the general population is 100 (SD 15), 
with higher IQ WISC-III-NL test scores indicating higher intelligence. For CBCL and YSR, data were represented as T scores, with a mean average of 50 and an SD of 10 in the general population, with higher scores indicative of more problems. The Rey complex 
figure test (for which a higher score suggests a better visual-spatial memory) and CHQ-PF50 (for which a higher score suggests a better quality of life) are presented using Z scores, with 0 representing the mean for the normal sample with an SD of 1. Teacher-reported school performance was calculated on a scale from 2 to 10, by summation of 5-point scores on topics of language and arithmetic, in which higher scores were given for greater ability in each area. For teacher-reported school performance, Stroop colour–word test (for which a lower score suggests better attention), and grooved pegboard test (for 
which a lower score suggests better fine motor coordination), raw scores were used, since no appropriate normal groups are available for the entire age range. Measurements taken before and after administration of study drug were done by the same neuropsychologist (either ABR or EP). Adverse events and study compliance were monitored by monthly 
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telephone contact and by visits to the outpatient clinic at baseline and at 1, 3, 6, 9, and 12 
months. Adverse events were classified according to WHO adverse reaction terminology and graded according to the National Cancer Institute common terminology criteria for adverse events. Blood was drawn at baseline and at 1, 6, 9, and 12 months to measure: alanine aminotransferase, aspartate aminotransferase, and creatine phosphokinase to screen for laboratory adverse events; and total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides to assess lower limits of lipid concentrations and to monitor compliance. Further details on procedures are presented in the appendix. 
Statistical analysis We used data from the intention-to-treat population—which consisted of all participants with outcome data—for all primary and secondary analyses, without imputation of missing values. Data from all patients were used for safety analyses—even those without efficacy outcome data. We analysed primary and secondary outcome measures using linear 
regression for the effect of treatment group on the score at 12 months, adjusted for baseline performance in the bivariable analysis and adjusted for baseline performance, age, and sex in the multivariable analysis. The cutoff level for significance was set at p<0•05, ignoring multiple testing. We analysed lipid blood concentrations using the generalised linear mixed model procedure with the interaction of time and treatment as the variable of interest. Sample size calculation suggested that inclusion of 84 participants (85% power; 
α=0•05) would be sufficient to detect a clinically relevant treatment effect of 7•5 full-scale 
intelligence points (0•5 SD), adjusted for baseline performance, and an increase or decrease of 5 T-score points (SD 0•5) for attention problems and internalising behavioural problems. Inclusion of 84 participants would lead to greater than 80% power on the coprimary outcome measures of attention problems and internalising behavioural problems. Because of low inclusion rates, the protocol was amended from 90% power and 106 participants to 85% power and 84 participants in the second recruitment year, without outcome knowledge and with approval from review boards. We planned the analysis before unmasking according to the study protocol. All data were analysed using IBM SPSS Statistics for Windows (version 20.0). This trial is registered with the Netherlands Trial Register, number NTR2150. 
Role of the funding sources The sponsors of the study had no role in the conception and design of the trial, the collection, analysis, and interpretation of the data, the writing of the manuscript, or the decision to publish the results. All authors had full access to all of the data in the study, and EL, YE, and HAM had final responsibility for the decision to submit for publication. 
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For the study protocol see http://www.erasmusmc.nl/nf1-simcoda  
Results We screened 343 patients for eligibility, of whom 221 were eligible. Between March 9, 2010, and March 6, 2012, we obtained informed consent from 84 patients or their parents. 
They were randomly assigned to 12 months of treatment with simvastatin (n=43) or 
placebo (n=41). Two patients in the placebo group were lost to follow-up before outcome could be assessed because they had behavioural problems that required drug therapy. Two participants in the placebo group discontinued study medication, but were available for 
outcome assessment (figure 1). Median compliance per patient was 96% (IQR 93–100), measured by counting returned capsules. Baseline demographic and disease characteristics were generally balanced between both treatment groups, although more patients in the simvastatin group were male than in the placebo group (table 1). At baseline, average full-scale intelligence was 83·3 points (SD 15·6) and 46 (55%) participants had attention problems scored on the CBCL of more than 1 SD above the mean of the general population. Median age was 11·5 years (range 7·9–16·0). 12 months of simvastatin had no significant effect on full-scale intelligence (treatment effect –1·3 IQ points [95% CI –3·8 to 1·3]; 
p=0·33), attention problems (–1·6 T-score points [–4·3 to 1·0]; p=0·23), or internalising behavioural problems (–0·1 [–3·3 to 3·1]; p=0·96) when adjusted for baseline performance (table 2). Additional adjustment for age and sex produced similar results (table 2). Simvastatin had no significant effects on any of the secondary outcome measures, including visual-spatial memory and attention (table 2). Figure 2 shows the standardised treatment effects on primary and secondary outcome measures. After 1 month (10 mg simvastatin per day), mean total cholesterol in the simvastatin group had decreased by 0·78 mmol/L (95% CI 0·54–1·03) more than it had in the placebo group and LDL cholesterol decreased by 0·79 mmol/L (0·56–1·01). Cholesterol concentrations had decreased no further at 6, 9, or 12 months. HDL cholesterol and triglycerides remained stable over the course of the study (appendix). Most adverse events were mild or moderate and frequency was similar between groups (table 3). 38 (88%) of 43 patients in the simvastatin group and 39 (95%) of 41 patients in the placebo group reported at least one adverse event. No increased incidence of myalgia, myopathy, or rhabdomyolysis was reported in patients given simvastatin compared with patients given placebo (appendix). Serious adverse events occurred in six patients: two in the simvastatin group and four in the placebo group. These events included continuing growth of plexiform neurofibromas (in two patients receiving simvastatin and one patient receiving placebo) and progressive scoliosis (two patients receiving placebo), all requiring surgery, and hospital admission for gastritis (one patient receiving placebo). 
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Results of laboratory screens showed a few mild and transient increases in liver enzymes 
and creatine kinase in both groups (table 3); none led to cessation of treatment. No participants reached the predefined lower limits for total cholesterol, HDL-cholesterol, or triglycerides (non-fasting). In the simvastatin group, seven children had one (n=3) or more 
(n=4) LDL cholesterol measurements below the predefined lower threshold, but no action was recommended by the data and safety monitoring board, since other values were within the normal range. Nine (53%) of 17 girls receiving simvastatin advanced one or more Tanner stages of puberty during the trial, compared with 16 (67%) of 24 receiving placebo. 14 (54%) of 26 boys receiving simvastatin and seven (54%) of 13 receiving placebo advanced one or more Tanner stages. Two girls in the placebo group were not included in this analysis because they did not undergo postbaseline Tanner stage assessments. 
Discussion Here we present the outcome of our randomised, doublemasked, placebo-controlled trial aimed at improving cognitive deficits in children with neurofibromatosis type 1. Our results showed that simvastatin treatment for 12 months had no effect on full-scale intelligence, attention problems, or internalising behavioural problems. Moreover, we found no indications of efficacy on a carefully selected range of predefined secondary outcome measures. Hence, this trial refutes a role for simvastatin in treatment of cognitive or behavioural problems in children with neurofibromatosis type 1. Unfortunately, despite the many promising drugs that have been identified in mouse models of cognitive disorders, translational studies with placebo-controlled trial designs are rare for cognitive disorders caused by single-gene mutations. This situation is also true for neurofibromatosis type 1 (panel). The absence of good clinical studies encourages off -label prescription, which is a major concern, particularly when the drug is readily available to the patient. In this study, the cognitive and behavioural profile of the study population at baseline (table 1) was fairly representative of the cognitive profile in the general neurofibromatosis type 1 population.3–5,8 Sample size was adequate, because we could confidently rule out a positive change of more than 1·3 points in full-scale intelligence, a reduction of attention problems of more than 4·3 T-score points, and a reduction of internalising behavioural problems of more than 3·3 T-score points (table 2). Furthermore, we achieved a low attrition rate and high medication compliance, which suggests that medium-term to long-term trials for cognitive dysfunction are feasible in this population. The dosing was based on the maximum recommended daily dose for treatment of children with familial hypercholesterolaemia.19 At least in the liver, maximal inhibition of the HMG-CoA reductase pathway was achieved in patients on simvastatin, shown by the substantial reduction of blood cholesterol concentrations after 1 month (appendix). Whether similar inhibition of the HMG-CoA reductase pathway was achieved in the brain is unknown. It is possible that higher doses are necessary to achieve biological effects in human beings. 
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However, increasing the dose would increase safety concerns, including the risk of myopathy, which was 30 times higher (0·9%) in adults on 80 mg per day of simvastatin than in those on 20 mg per day.23 Although 12 months of simvastatin was not related to any adverse events, this study was not powered to detect rare effects. Of note, a lower proportion of girls receiving simvastatin advanced one or more pubertal stages than did those receiving placebo, which was non-significant and might simply be attributed to age differences between the groups. Nonetheless, future studies of statin treatment in other populations of normocholesterolaemic children and adolescents should monitor puberty development. We assumed 12 months of treatment was long enough to measure effects on full-scale intelligence. In support of this view, results of 1 year randomised studies showed that full-scale intelligence can improve in children with attention deficit hyperactivity disorder who receive stimulant medication24 and in healthy children taking music lessons.25 However, how much time a human brain would need to show a discernible effect on full-scale intelligence or other neuropsychological tests is unknown. In view of the broad range of tests and validated questionnaires in this study, selection of different outcome measures would have been unlikely to change the conclusions on the effect of simvastatin treatment.  Our study population was selective in two ways. First, it was limited to children aged 8–16 years, so a therapeutic benefit in younger children cannot be excluded. Second, of 343 children who were screened, 64 (19%) were excluded from the trial because they had been taking stimulant medication. Despite this selection, 46 (55%) participants had attention problems of more than 1 SD above population norms, suggesting that attention problems were prevalent in the study population. Children were eligible for this study irrespective of their baseline neuropsychological test scores, since several difficulties are associated with selecting participants according to baseline performance. First and most important, the subgroup of children with neurofibromatosis type 1 that might benefit most from drug treatment is unknown. Also, any upper or lower limit of functioning would be arbitrary. Therefore, we chose to recruit children irrespective of baseline deficits and to do subgroup analyses if any benefits were noted in primary analysis. Differences between lovastatin and simvastatin are unlikely to explain our negative results, since the rationale for using statins in neurofibromatosis type 1 is their ability to reduce Ras farnesylation, for which mevalonate is an obligate precursor in the synthesis of both farnesyl moieties and cholesterol. However, we cannot completely exclude off -target effects that are exclusive to lovastatin. A phase 2 randomised trial of lovastatin for 16 weeks is underway to assess its effects on visual spatial learning and sustained attention in children with neurofibromatosis type 1.26 The preclinical studies on which this study was predicated were done exclusively in a mouse model of neurofibromatosis type 1, for which underlying human pathophysiological changes might not be sufficiently analogous. For instance, we 
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cannot exclude that certain pathological changes frequently reported in patients with neurofibromatosis type 1, such as microstructural changes of white brain matter identified with diffusion tensor imaging27 or changes in corpus callosum thickness,28 contribute to cognitive deficits and might not be responsive to statins. However, important similarities in neurophysiology are reported between patients with neurofibromatosis type 1 and the 
Nf1+/– mouse model. For example, neurofibromatosis type 1 seems to affect working memory and attention in both human beings and rodents through cortical inhibition of corticostriatal pathways.13 Additionally, behavioural deficits in patients with neurofibromatosis type 1 and mice are very similar: most notably in their analogous deficits in (virtual) watermaze performance.11,29,30 Mechanistically, GABAergic dysfunction has been observed in both the mouse model and patients.11,12,31 Nevertheless, in view of the results of our trial, further insight into the pathophysiology of neurofibromatosis type 1 will be necessary to explore other targetable disease mechanisms. 
Panel: Research in context 
Systematic review We did a systematic search of PubMed on July 8, 2013, for additional cognitive trials in neurofibromatosis type 1. Search terms included “neurofibromatosis”, “cognition”, “attention”, “behaviour”, and “clinical trial”. Of 25 articles found, four described three clinical trials in patients with neurofibromatosis type 1. A 12 week randomised placebo-controlled trial in 61 children with neurofibromatosis type 1 showed no effect of simvastatin on cognitive function and MRI abnormalities, with the notable exception of the significant effect on one secondary outcome measure: the object assembly subtask of the Wechsler intelligence scale for children.6 Furthermore, results of a phase 1 single-arm open-label study of lovastatin in 23 children with neurofibromatosis type 1 suggested lovastatin improved memory and attention, accompanied by normalisation of default network functional connectivity measured with resting-state functional MRI in a subset of the participants.15,16 These seemingly encouraging results might be attributable to normal cognitive development, test–retest improvements, or placebo effects. A third study was a single-arm 1 year study of methylphenidate to treat attention problems in children with neurofibromatosis type 1 and comorbid attention deficit hyperactivity disorder, and results showed a decrease in attention problems in children who received the drug.22 
Interpretation In this 12 month trial, use of simvastatin provided no benefit over placebo on full-scale intelligence, behavioural problems, visual-spatial memory, attention, motor coordination, school performance, and quality of life. These findings are in contrast with results from the previous single-arm study,15,16 but largely consistent with the smaller randomised 
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controlled trial that measured short-term effects of simvastatin on neuropsychological test scores and MRI abnormalities.6 We conclude that the number of trials is limited, and more studies are needed to identify effective treatments for cognitive and behavioural problems in children with neurofibromatosis type 1. 
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Tables and figures 
Figure 1: Trial profile ADHD = attention deficit hyperactivity disorder   
16 
 
 Simvastatin (n= 43) Placebo (n= 41) 
Age in years at baseline, median (IQR) Male sex, n (%) 11·1 (9·2 – 13·0) 26 (61) 11·8 (10·2 – 14·7) 13 (32) Full-scale intelligence, mean (SD) 83·8 (16·1) 82·7 (15·3) Attention problems Average T-score, mean (SD)  61·1 (8·9)  62·8 (8·3) Internalizing behavioural problems Average T-score, mean (SD)  55·2 (10·7)  56·7 (10·1) NF1 disease severity, n (%) Minimal Mild Moderate  Severe 
 18 (42) 7 (16) 17 (40) 1 (2) 
 21 (51) 4 (10) 15 (37) 1 (2) Genetic mutation type, n (%) Truncating mutation In-frame del-dup or missense mutation Microdeletion Unclassified variant 
 24 (56) 18 (42) 1 (2) 0 (0) 
 28 (68) 11 (27) 1 (2) 1 (2) NF1 inheritance, n (%) Familial Sporadic Unknown 
 22 (51) 21 (49) 0 (0) 
 19 (46) 20 (49) 2 (5) Education type, n (%) Regular Special  20 (46) 23 (54)  24 (58) 17 (42) Parental Occupation, n (%)  Lower Middle Higher 
 18 (42) 13 (30) 12 (28) 
 13 (32) 15 (37) 13 (32) Total cholesterol, mean (SD), mmol/L 4·17 (0·57) 4·30 (0·75) LDL cholesterol, mean (SD), mmol/L 2·33 (0·54) 2·41 (0·65) Dose group in month 3-12, n (%) 20 mg/d or placebo 40 mg/d or placebo  29 (67) 14 (33)  23 (56) 18 (44) (Table 1) 
17 
 
Table 1: Baseline characteristics. NF1 disease severity of NF1 was scored according to the Riccardi scale modified to exclude cognitive aspects of NF1.6 Classification of parental occupation 
was done according to the Dutch central bureau of statistics, CBS. Abbreviations: IQR, interquartile 
range; LDL, low-density lipoprotein. 
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 Simvastatin mean (SD) 
Placebo 
mean (SD) 
β adjusted 
for baseline 
score 
p-
value 
β adjusted for 
baseline score, 
age and sex 
p-value 
Primary outcome measures       
Full-scale intelligence (IQ)a 
Baseline 
12 months 
n = 43 
83·8 (16·1) 
85·7 (18·0) 
n = 39 
82·3 (15·5) 
85·4 (16·4) 
 
-1·3  
(-3·8 – 1·3) 0·33 
 
-0·8  
(-3·4 – 1·8) 0·56 
Attention problemsb, c 
Baseline 
12 months 
n = 42 
61·1 (9·0) 
58·8 (7·4) 
n = 39 
62·0 (7·6) 
60·9 (9·0) 
 
-1·6  
(-4·3 – 1·0) 
 
 
0·23 
 
-2·2  
(-5·0 – 0·5) 
 
 
0·11 
Internalizing behavioural 
problemsb, c 
Baseline 
12 months 
 
n = 42 
54·9 (10·6) 
54·0 (9·0) 
 
n = 39 
56·1 (10·0) 
54·9 (10·0) 
 
 
-0·1  
(-3·3 – 3·1) 0·96 
 
 
0·0  
(-3·4 – 3·4) 0·99 
Secondary outcome 
measures       
Visual-spatial memory 
(Rey Complex Figure –  
delayed recall)a, d 
Baseline 
12 months 
 
 
n = 42 
-2·0 (0·9) 
-1·9 (1·0) 
 
 
n = 39 
-2·0 (1·1) 
-1·7 (1·2) 
 
 
 
-0·2  
(-0·6 – 0·2) 0·34 
 
 
 
-0·1 
(-0·6 – 0·3) 0·50 
Attention (Stroop Colour 
Word Interference)b, e 
Baseline 
12 months 
 
n = 41 
72 (39) 
59 (31) 
 
n = 37 
64 (45) 
47 (27) 
 
 
7·5  
(-1·3 – 16·2) 0·14 
 
 
2·8  
(-5·9 – 11·7) 0·55 
Teacher rating a, f 
Baseline 
12 months 
n = 34 
5·8 (2·2) 
6·2 (1·9) 
n = 30 
5·7 (2·4) 
6·0 (1·9) 
 
0·2  
(-0·6 – 0·9) 0·64 
 
0·1  
(-0·7 – 1·0) 0·74 
Psychosocial  
Quality of Lifea, g 
Baseline 
12 months 
 
n = 40 
-0·06 (0·80) 
0·15 (0·69) 
 
n = 38 
-0·07 (0·74) 
0·13 (0·80) 
 
 
0·02 
(-0·22 – 0·25) 0·89 
 
 
0·04  
(-0·20 – 0·29) 0·72 
Internalizing behavioural 
problems 
(Self-reported)b, h 
Baseline 
12 months 
 
 
n = 23 
56·4 (11·9) 
51·9 (9·9) 
 
 
n = 24 
53·0 (8·3) 
51·7 (9·8) 
 
 
 
-1·7  
(-6·5 – 3·1) 0·48 
 
 
 
-2·5  
(-8·1 – 3·1) 0·37 
Grooved Pegboard, 
dominant hand 
(fine motor coordination)b 
Baseline 
12 months 
 
 
n = 43 
94 (29) 
80 (18) 
 
 
n = 39 
84 (23) 
79 (18) 
 
 
 
-3·8  
(-8·8 – 1·3) 0·14 
 
 
 
-4·9  
(-10·2 – 0·3) 0·07  (Table 2) 
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Table 2: Primary and secondary outcome measures at baseline and 12-month follow-up.  a) Higher is better. b) Lower is better. Reasons for missing data: c) questionnaire not returned by 
parents, simvastatin n=1; d) omitted from test-battery erroneously, simvastatin n=1; e) not able to 
perform due to learning disability, placebo n=2, simvastatin n=2; f) arithmetic and language topics 
were qualified by teachers as “not applicable”, placebo n=9, simvastatin n=9;  g) questionnaire not 
returned, simvastatin n=1, essential items not filled out on checklist, placebo n=1, simvastatin n=2; h) self-report cannot be administered to children <11 years, placebo n=15, simvastatin n=20. Values represent mean (SD).   
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 Simvastatin  
(n=43)  
Placebo  
(n=41)  
Adverse events by system organ class Event n  
(patient n)  
Event n  
(patient n)  
 Grade 1-2 Grade 3 Grade 1-2 Grade 3 Gastro-intestinal system disorders 23 (17)  25 (21) 1 (1) Body as a whole - general disorders 16 (16)  25 (20)  Skin and appendages disorders 12 (10)  11 (10)  Musculo-skeletal system disorders 8 (7)  13 (11)  Respiratory system disorders 12 (11)  5 (5)  Central and peripheral nervous system disorders 9 (8)  6 (6)  Neoplasms (e.g. aggravated neurofibroma) 2 (2) 2 (2) 3 (2) 1 (1) Psychiatric disorders 2 (2)  4 (4)  Urinary system disorders 2 (2)  4 (4)  Secondary events, e.g. post-operative pain 3 (3)  1 (1) 2 (2) Resistance mechanism disorders 4 (4)  2 (2)  Vision disorders 1 (1)  3 (3)  Other systems 1 (1)  3 (3)  
Laboratory Adverse Events     Elevated alanine transaminase (ALT) 6 (6)  1 (1)  Elevated aspartate transaminase (AST) 3 (3)  5 (5)  Elevated creatine kinase (CK) 1 (1)  1 (1)  
Puberty development n (%)  n (%)  
Girls n=17  n=24  No change 8 (47)  8 (33)  
Changed ≥1 Level 9 (53)  16 (67)  
Boys n=26  n=13  No change 12 (46)  6 (46)  
Changed ≥1 Level 14 (54)  7 (54)  
All n=43  n=37  No change 20 (47)  14 (38)  
Changed ≥1 Level 23 (53)  23 (62)  
 
Table 3: Adverse events Data are number of events (number of patients who had an event). Adverse events are grouped by system organ class according to WHO adverse reaction terminology. A complete list of adverse events is presented in the online appendix at www.lancet.com/neurology. 
 
